.png
)
Feb 22, 2025 In a major regulatory move, India's Central Drug Regulator (CDSCO) have ordered the immediate withdrawal of manufacturing and export permissions for all Tapentadol-Carisoprodol combinations. This decisive action comes in response to growing concerns over their misuse…
The Central Drugs Standard Control Organization (CDSCO), under the Directorate General of Health Services, Government of India, has taken another significant step towards digital transformation. As per the circular dated 12th February 2025, CDSCO has introduced an online provision for…
Jan 6, 2025 In a significant development for Micro, Small, and Medium Enterprises (MSME) in the pharmaceutical sector, the Ministry of Health and Family Welfare (MoHFW) has proposed an extension for compliance with the updated Good Manufacturing Practice (GMP) standards…
December 30, 2024 In a bid to streamline the process of clinical trial approvals in India, the Central Drugs Standard Control Organization (CDSCO) has enhanced the functionalities of the Sugam Portal, allowing sponsors and researchers to efficiently submit clinical trial…
December 16, 2024 In a significant move to support patients battling rare diseases, the Central Drugs Standard Control Organization (CDSCO), India’s apex drug regulatory body, has directed drug regulators across the country to fast-track the approval process for medications and…